461 related articles for article (PubMed ID: 35620395)
41. Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.
Feng L; Shen F; Zhou J; Li Y; Jiang R; Chen Y
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32190895
[TBL] [Abstract][Full Text] [Related]
42. Aberrant Hypomethylation of Solute Carrier Family 6 Member 12 Promoter Induces Metastasis of Ovarian Cancer.
Sung HY; Yang SD; Park AK; Ju W; Ahn JH
Yonsei Med J; 2017 Jan; 58(1):27-34. PubMed ID: 27873492
[TBL] [Abstract][Full Text] [Related]
43. Epigenetic enzyme mutations as mediators of anti-cancer drug resistance.
Chen S; Zhao Y; Liu S; Zhang J; Assaraf YG; Cui W; Wang L
Drug Resist Updat; 2022 Mar; 61():100821. PubMed ID: 35219075
[TBL] [Abstract][Full Text] [Related]
44. Role of DNA De-methylation intermediate '5-hydroxymethylcytosine' in ovarian cancer management: A comprehensive review.
Bisht D; Arora A; Sachan M
Biomed Pharmacother; 2022 Nov; 155():113674. PubMed ID: 36099791
[TBL] [Abstract][Full Text] [Related]
45. MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1.
Vescarelli E; Gerini G; Megiorni F; Anastasiadou E; Pontecorvi P; Solito L; De Vitis C; Camero S; Marchetti C; Mancini R; Benedetti Panici P; Dominici C; Romano F; Angeloni A; Marchese C; Ceccarelli S
J Exp Clin Cancer Res; 2020 Jan; 39(1):3. PubMed ID: 31898520
[TBL] [Abstract][Full Text] [Related]
46. Epigenetic Modifications in Tumor-Associated Macrophages: A New Perspective for an Old Foe.
Niu Y; Chen J; Qiao Y
Front Immunol; 2022; 13():836223. PubMed ID: 35140725
[TBL] [Abstract][Full Text] [Related]
47. Epigenomics and ovarian carcinoma.
Maldonado L; Hoque MO
Biomark Med; 2010 Aug; 4(4):543-70. PubMed ID: 20701443
[TBL] [Abstract][Full Text] [Related]
48. Drug resistance in colorectal cancer: An epigenetic overview.
Luo M; Yang X; Chen HN; Nice EC; Huang C
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188623. PubMed ID: 34481016
[TBL] [Abstract][Full Text] [Related]
49. The epigenetics of ovarian cancer drug resistance and resensitization.
Balch C; Huang TH; Brown R; Nephew KP
Am J Obstet Gynecol; 2004 Nov; 191(5):1552-72. PubMed ID: 15547525
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of Epigenetic Drug Targeting of Heterogenous Tumor Cell Fractions Using Potential Biomarkers of Response in Ovarian Cancer.
Singh AK; Chandra N; Bapat SA
Clin Cancer Res; 2015 Nov; 21(22):5151-63. PubMed ID: 26130461
[TBL] [Abstract][Full Text] [Related]
51. The role of epigenetic modifications in drug resistance and treatment of breast cancer.
Karami Fath M; Azargoonjahromi A; Kiani A; Jalalifar F; Osati P; Akbari Oryani M; Shakeri F; Nasirzadeh F; Khalesi B; Nabi-Afjadi M; Zalpoor H; Mard-Soltani M; Payandeh Z
Cell Mol Biol Lett; 2022 Jun; 27(1):52. PubMed ID: 35764927
[TBL] [Abstract][Full Text] [Related]
52. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.
Nogales V; Reinhold WC; Varma S; Martinez-Cardus A; Moutinho C; Moran S; Heyn H; Sebio A; Barnadas A; Pommier Y; Esteller M
Oncotarget; 2016 Jan; 7(3):3084-97. PubMed ID: 26625211
[TBL] [Abstract][Full Text] [Related]
53. Regulation of epigenetic modifications in the head and neck tumour microenvironment.
Liu H; Wang D; Yang Z; Li S; Wu H; Xiang J; Kan S; Hao M; Liu W
Front Immunol; 2022; 13():1050982. PubMed ID: 36405713
[TBL] [Abstract][Full Text] [Related]
54. Epigenetic regulation of proprotein convertase PACE4 gene expression in human ovarian cancer cells.
Fu Y; Campbell EJ; Shepherd TG; Nachtigal MW
Mol Cancer Res; 2003 Jun; 1(8):569-76. PubMed ID: 12805404
[TBL] [Abstract][Full Text] [Related]
55. Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2.
Xu L; Zhang B; Li W
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576437
[TBL] [Abstract][Full Text] [Related]
56. Multivalent epigenetic marks confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells.
Bapat SA; Jin V; Berry N; Balch C; Sharma N; Kurrey N; Zhang S; Fang F; Lan X; Li M; Kennedy B; Bigsby RM; Huang TH; Nephew KP
Epigenetics; 2010; 5(8):716-29. PubMed ID: 20676026
[TBL] [Abstract][Full Text] [Related]
57. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.
Wilting RH; Dannenberg JH
Drug Resist Updat; 2012; 15(1-2):21-38. PubMed ID: 22356866
[TBL] [Abstract][Full Text] [Related]
58. Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
Fejzo MS; Chen HW; Anderson L; McDermott MS; Karlan B; Konecny GE; Slamon DJ
Gynecol Oncol; 2021 Feb; 160(2):539-546. PubMed ID: 33229045
[TBL] [Abstract][Full Text] [Related]
59. Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells.
Karaca B; Atmaca H; Bozkurt E; Kisim A; Uzunoglu S; Karabulut B; Sezgin C; Sanli UA; Uslu R
Mol Biol Rep; 2013 Jun; 40(6):3925-33. PubMed ID: 23269627
[TBL] [Abstract][Full Text] [Related]
60. Advances in the role of GPX3 in ovarian cancer (Review).
Geng D; Zhou Y; Wang M
Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38299269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
